3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Enrolling by invitation
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Colorectal Neoplasms
8
Breast Neoplasms
7
Uterine Cervical Neoplasms
5
Lung Neoplasms
5
Hematopoietic and Lymphatic System Neoplasm
4
Papillomavirus Infections
3
Liver Neoplasms
2
Hematologic Neoplasms
2
Carcinoma, Intraductal, Noninfiltrating
2
Carcinoma, Hepatocellular
2
Pyloric Stenosis, Hypertrophic
1
Prostatic Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Overweight
1
Obesity
1
Neoplasms
1
Neoplasm Metastasis
1
Multiple Myeloma
1
Lymphoma
1
Liver Diseases
1
HER2+ Metastatic Breast Cancer (MBC)
1
Fibrosis
1
Diabetes Mellitus
1
Colorectal Cancer Screening
1
Colonic Neoplasms
1
Cardiovascular Diseases
1
Cancer Screening
1
Interventions
Oxaliplatin
27
Fluorouracil
23
Leucovorin
22
Cetuximab
22
Bevacizumab
21
Nivolumab
16
Capecitabine
16
Irinotecan
15
pembrolizumab
11
Magnetic Resonance Spectroscopy
11
Specimen Handling
10
encorafenib
8
Folfox protocol
7
trifluridine tipiracil drug combination
6
Ipilimumab
6
Exercise
6
fludarabine
5
cemiplimab
5
Trastuzumab
5
Gemcitabine
5
Cyclophosphamide
5
Cisplatin
5
Blood Specimen Collection
5
Biopsy
5
regorafenib
4
pertuzumab
4
adagrasib
4
Trifluridine
4
Pemetrexed
4
Immune Checkpoint Inhibitors
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Colonic Neoplasms
×
Patient Navigation
×
1 year
×
Clear all
NCT06458998
2026-02-23
GTI
University of Pittsburgh
Phase NA
Enrolling by invitation
30,300 enrolled